H-E-B disburses $585,000 to Texas educators
AUSTIN, Texas — H-E-B on Friday announced statewide winners of the 12th annual H-E-B Excellence in Education Awards during a banquet at Austin’s Hilton Hotel. At the ceremony, H-E-B chairman and CEO Charles Butt disbursed $585,000 in cash awards and grants and personally congratulated 23 educators, campuses, school districts and one early childhood agency for being among the best in Texas.
Former CNN anchor and current documentary producer Soledad O’Brien delivered the keynote address to a ballroom packed with hundreds of educators, elected officials, community leaders and H-E-B employees.
H-E-B launched the Excellence in Education Awards program in cooperation with the Texas Association of School Administrators in 2002 as a positive way to support public education in Texas by spotlighting best practices and celebrating the passion and creativity of Texas educators. Since its inception, H-E-B has given more than $6.5 million, making it the state’s largest monetary award program dedicated to education, the grocer reported.
FDA approves Merck cholesterol drug
WHITEHOUSE STATION, N.J. — The Food and Drug Administration has approved a new drug made by Merck for treating high cholesterol, the drug maker said.
Merck announced the approval of Liptruzet (ezetimibe and atorvastatin). The drug combines two preexisting cholesterol drugs: ezetimibe, which Merck markets under the brand name Zetia, and atorvastatin, which Pfizer markets under the name Lipitor. Both drugs are available as generics, but because Liptruzet is a novel combination of them, it required FDA approval as a new drug.
"A significant percentage of patients are unable to lower their [low-density lipoprotein] cholesterol to recommended levels despite treatment," Baylor College of Medicine professor Peter Jones said. "Along with a healthy diet, Liptruzet is an effective new lipid-lowering treatment option that may help address this unmet need as the complementary actions of its components can provide significant additional LDL lowering beyond atorvastatin therapy alone."
FDA approves Bristol-Myers Squibb’s Sustiva for HIV in infants, toddlers
PRINCETON, N.J. — The Food and Drug Administration has approved a drug for HIV in infants and toddlers.
Bristol-Myers Squibb said the FDA approved Sustiva (efavirenz) for HIV-1 in pediatric patients as young as 3 months and weighing at least 7.7 pounds. The approval includes a "capsule sprinkle" administration option for those who can’t swallow capsules or tablets, whereby capsules are broken open and the contents are sprinkled on food or a beverage. The new approval was under a supplemental new drug application, or sNDA, which means the drug was approved for a new use in addition to approvals it had already received; the FDA originally approved Sustiva in 1998 for children ages 3 years and older.
"Bristol-Myers Squibb recognizes the importance of offering alternative methods of administration of HIV medicines, including for pediatric patients who cannot swallow tablets or capsules, and their caregivers who help manage their treatment," Bristol-Myers Squibb SVP global development and medical affairs Brian Daniels said. "This approval is one example of our enduring commitment to the HIV patient community."